Streetbeat News

Products Services

EXAS

TwinStrand Biosciences has entered into an agreement with Exact Sciences to exclusively license its patent estate in the cell-free nucleic acid sequencing space. The license pertains to TwinStrand's Duplex Sequencing® error-correction technology, which significantly enhances the accuracy of next-generation sequencing.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:14 pm

SSRM

SSR Mining has announced that its FY24 production forecast for Marigold, Seabee, and Puna remains unchanged at 340,000-380,000 gold equivalent ounces.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:13 pm

MSFT

NTDOY

SONY

Microsoft's Q4 earnings report shows a 42% decline in Xbox hardware sales, continuing a downward trend. However, overall gaming revenue surged 44% year-over-year, driven by the acquisition of Activision Blizzard. Industry-wide, major console makers like Sony and Nintendo also saw declines in hardware sales.

Portfolio Pulse from Franca Quarneti

July 31, 2024 | 8:11 pm

META

Meta Platforms expects its full-year 2024 total expenses to be in the range of $96-99 billion, unchanged from its prior outlook. The company also anticipates increased operating losses for Reality Labs due to ongoing product development and scaling investments.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:08 pm

HLVX

HilleVax plans to reduce its workforce by approximately 40%, affecting around 41 employees. This move aims to preserve cash while continuing the development of its HIL-214 and HIL-216 norovirus vaccine candidates and related business activities.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:05 pm

QCOM

Qualcomm Inc (NASDAQ:QCOM) reported strong Q3 earnings with revenue and EPS beating estimates. Revenue was $9.4 billion, up 11% YoY, and EPS was $2.33. The company saw significant growth in its QCT segment, particularly in automotive. Qualcomm provided positive Q4 guidance and announced upcoming product launches.

Portfolio Pulse from Chris Katje

July 31, 2024 | 8:04 pm

ALXO

ALX Oncology reported positive data from its ASPEN-06 Phase 2 trial, showing that the evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm. In patients with fresh HER2-positive biopsies, the ORR was 54.8% versus 23.1% in the control, indicating a strong correlation between HER2 expression and evorpacept efficacy.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:03 pm

AMC

SONY

AMC Entertainment Holdings (NYSE:AMC) is set to release a new concert film featuring Usher, titled 'Usher: Rendezvous In Paris,' in collaboration with Trafalgar Releasing and Sony Music Vision, a unit of Sony Group Corp (NYSE:SONY). The film will be shown in over 2,000 theaters globally, including 1,000 in the U.S., from September 12 to 15. This move follows successful concert films from Taylor Swift and Beyoncé, potentially adding a new revenue stream for AMC.

Portfolio Pulse from Chris Katje

July 31, 2024 | 8:01 pm

ALXO

ALX Oncology shares are trading lower following the announcement of an upcoming investor call and webcast to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for advanced HER2-positive gastric cancer.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 7:44 pm

JNJ

The FDA has issued a warning against the use of Megadyne Mega Soft Pediatric Patient Return Electrodes for any age group. Instead, it recommends using Megadyne Mega 2000 and Mega Soft Patient Return Electrodes only for patients aged 12 years and older.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 7:35 pm